C-CAR168 for autoimmune brain diseases not helped by standard treatments
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a new cell therapy called C-CAR168 for people with autoimmune diseases affecting the brain and spinal cord, such as multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, or stiff person spectrum disorder. It is for patients whose condition has not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, or stiff person spectrum disorder for at least 6 months.
- Your disease has not responded well to standard therapies.
- Your major organs (bone marrow, heart, lungs, liver, kidneys) are working well enough.
- You do not have active infections like hepatitis B or C, HIV, or syphilis.
- You have not had a live vaccine in the last 4 weeks, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called C-CAR168 for people with certain autoimmune diseases that have not improved with standard therapies. It aims to see if this treatment can help control the disease.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a universal CAR-T cell treatment for people with autoimmune diseases of the nervous system that haven't responded to standard therapies. It aims to see if this therapy can help control diseases like neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multiple sclerosis.
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
This early-stage trial tests a new type of immune cell therapy (CAR T-cells) against several relapsed or hard-to-treat autoimmune diseases that affect the nervous system. The goal is to see if this treatment can safely calm the immune system and improve symptoms.
Hear when a new Neuromyelitis Optica Spectrum Disorders (NMOSD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.